Recent changes in Europe`s MDMA/ecstasy market
... production is destined for internal markets, with Germany and the United Kingdom being the most common destinations. There is no evidence of MDMA being imported into the European Union (EU). Assessing recent trends in MDMA seizures is difficult due to the absence of data from some countries that are ...
... production is destined for internal markets, with Germany and the United Kingdom being the most common destinations. There is no evidence of MDMA being imported into the European Union (EU). Assessing recent trends in MDMA seizures is difficult due to the absence of data from some countries that are ...
500ct. 7.5-500 mg HCb and APAP Tablets[Watson[Base[rev2
... more than one acetaminophen containing product. The excessive intake of acetaminophen may be intentional to cause self-harm or unintentional as patients attempt to obtain more pain relief or unknowingly take other acetaminophencontaining products. The risk of acute liver failure is higher in individ ...
... more than one acetaminophen containing product. The excessive intake of acetaminophen may be intentional to cause self-harm or unintentional as patients attempt to obtain more pain relief or unknowingly take other acetaminophencontaining products. The risk of acute liver failure is higher in individ ...
Drug Formulary
... myriad of drugs that can be used to anesthetize animals--however most of them were not developed for use in animals and are therefore being used in an extra-label manner. Animal species differ in their responses to various drugs, and much of the information that we have about dosage, and especially ...
... myriad of drugs that can be used to anesthetize animals--however most of them were not developed for use in animals and are therefore being used in an extra-label manner. Animal species differ in their responses to various drugs, and much of the information that we have about dosage, and especially ...
Map and Application of States That Require a Prescription for
... Application and Exemptions Applies to any product that contains any quantity of ephedrine, a salt of ephedrine, an optical isomer of ephedrine, or a salt of an optical isomer of ephedrine. Products listed below are exempted if they may belawfully sold over the counter without a prescription under th ...
... Application and Exemptions Applies to any product that contains any quantity of ephedrine, a salt of ephedrine, an optical isomer of ephedrine, or a salt of an optical isomer of ephedrine. Products listed below are exempted if they may belawfully sold over the counter without a prescription under th ...
HIGHLIGHTS OF PRESCRIBING INFORMATION --------------------------WARNINGS AND PRECAUTIONS---------------------------
... • Open capsules, empty and mix the entire contents with yogurt, water, or orange juice. If the contents of the capsule include any compacted powder, a spoon may be used to break apart the powder. The contents should be mixed until completely dispersed. Consume the entire mixture immediately. It shou ...
... • Open capsules, empty and mix the entire contents with yogurt, water, or orange juice. If the contents of the capsule include any compacted powder, a spoon may be used to break apart the powder. The contents should be mixed until completely dispersed. Consume the entire mixture immediately. It shou ...
Map and Application of States That Require a Prescription for
... Application and Exemptions Applies to any product that contains any quantity of ephedrine, a salt of ephedrine, an optical isomer of ephedrine, or a salt of an optical isomer of ephedrine. Products listed below are exempted if they may belawfully sold over the counter without a prescription under th ...
... Application and Exemptions Applies to any product that contains any quantity of ephedrine, a salt of ephedrine, an optical isomer of ephedrine, or a salt of an optical isomer of ephedrine. Products listed below are exempted if they may belawfully sold over the counter without a prescription under th ...
Full Prescribing Information for CONCERTA® (methylphenidate HCl)
... problems. Although some serious heart problems alone carry an increased risk of sudden death, stimulant products generally should not be used in children or adolescents with known serious structural cardiac abnormalities, cardiomyopathy, serious heart rhythm abnormalities, or other serious cardiac p ...
... problems. Although some serious heart problems alone carry an increased risk of sudden death, stimulant products generally should not be used in children or adolescents with known serious structural cardiac abnormalities, cardiomyopathy, serious heart rhythm abnormalities, or other serious cardiac p ...
IOSR Journal of Dental and Medical Sciences (IOSR-JDMS)
... Intranasal Dexmedetomidine used pre-operatively in pediatric anaesthesia is especially useful in extremely anxious and uncooperative children as observed by Kain et al11 in relation to post operative behaviour problems.Kain et al 11determined that a patient’s anxiety level influences their immediate ...
... Intranasal Dexmedetomidine used pre-operatively in pediatric anaesthesia is especially useful in extremely anxious and uncooperative children as observed by Kain et al11 in relation to post operative behaviour problems.Kain et al 11determined that a patient’s anxiety level influences their immediate ...
Methadone-Drug Interactions
... literature and new cases appear monthly (Levy et al. 2000). As the tables in this document indicate, there are more than100 substances – medications, illicit drugs, OTC products, etc. – that can interact in some fashion to affect a patient’s response to methadone. Pharmacotherapy is increasingly com ...
... literature and new cases appear monthly (Levy et al. 2000). As the tables in this document indicate, there are more than100 substances – medications, illicit drugs, OTC products, etc. – that can interact in some fashion to affect a patient’s response to methadone. Pharmacotherapy is increasingly com ...
HYZAAR® HYZAAR® DS
... losartan, in some cases after the first dose. It is more likely to occur in patients who are volumedepleted by diuretic therapy, dietary salt restriction, dialysis, diarrhea, or vomiting. In these patients, because of the potential fall in blood pressure, therapy should be started under close medica ...
... losartan, in some cases after the first dose. It is more likely to occur in patients who are volumedepleted by diuretic therapy, dietary salt restriction, dialysis, diarrhea, or vomiting. In these patients, because of the potential fall in blood pressure, therapy should be started under close medica ...
A Descriptive Study of Adverse Events from
... from 2 regional poison centers for human exposures to clenbuterol. Data collected after individual chart review, including review of individual case notes fields, included demographics, substances involved including coingestatants if known, reason for exposure/use of clenbuterol, dose, clinical effe ...
... from 2 regional poison centers for human exposures to clenbuterol. Data collected after individual chart review, including review of individual case notes fields, included demographics, substances involved including coingestatants if known, reason for exposure/use of clenbuterol, dose, clinical effe ...
Spiractin - Medicines.org.au
... Spironolactone has been shown to be tumorigenic in chronic toxicity studies performed in rats. It should be used only for approved indications. Unnecessary use of this drug should be avoided. In chronic toxicity studies of spironolactone in rats, changes were observed in the endocrine organs and the ...
... Spironolactone has been shown to be tumorigenic in chronic toxicity studies performed in rats. It should be used only for approved indications. Unnecessary use of this drug should be avoided. In chronic toxicity studies of spironolactone in rats, changes were observed in the endocrine organs and the ...
Full Prescribing Information for CONCERTA
... problems. Although some serious heart problems alone carry an increased risk of sudden death, stimulant products generally should not be used in children or adolescents with known serious structural cardiac abnormalities, cardiomyopathy, serious heart rhythm abnormalities, or other serious cardiac p ...
... problems. Although some serious heart problems alone carry an increased risk of sudden death, stimulant products generally should not be used in children or adolescents with known serious structural cardiac abnormalities, cardiomyopathy, serious heart rhythm abnormalities, or other serious cardiac p ...
Annex 1 - The plant and the drug - United Nations Office on Drugs
... can be done by hand or by machine in order to prepare it for storage and shipping. Sieving requires the plants to be dried first, which means an arid climate is essential. The resin and trichomes become powdery and brittle, and can be removed from the bulk of the plant matter by use of a screen and ...
... can be done by hand or by machine in order to prepare it for storage and shipping. Sieving requires the plants to be dried first, which means an arid climate is essential. The resin and trichomes become powdery and brittle, and can be removed from the bulk of the plant matter by use of a screen and ...
abnormalities, coronary artery disease, or other serious heart problems. (5.1)
... problems. Although some serious heart problems alone carry an increased risk of sudden death, stimulant products generally should not be used in children or adolescents with known serious structural cardiac abnormalities, cardiomyopathy, serious heart rhythm abnormalities, or other serious cardiac p ...
... problems. Although some serious heart problems alone carry an increased risk of sudden death, stimulant products generally should not be used in children or adolescents with known serious structural cardiac abnormalities, cardiomyopathy, serious heart rhythm abnormalities, or other serious cardiac p ...
Modelling of tolerance and rebound in normal and
... concentrations is seen within a few minutes of onset of treatment. This, together with the short half-life of NiAc implies that informative experiments for studying tolerance and rebound can be performed within a few hours of drug administration. Although it is known that binding of drugs to other r ...
... concentrations is seen within a few minutes of onset of treatment. This, together with the short half-life of NiAc implies that informative experiments for studying tolerance and rebound can be performed within a few hours of drug administration. Although it is known that binding of drugs to other r ...
the selection and use of essential medicines
... and Standards, and Secretary of the Expert Committee, also welcomed the participants. He noted that this would be the third Expert Committee operating under the new procedures approved in 2002. The full effect of these new procedures was now apparent in the careful and timely presentation of evidenc ...
... and Standards, and Secretary of the Expert Committee, also welcomed the participants. He noted that this would be the third Expert Committee operating under the new procedures approved in 2002. The full effect of these new procedures was now apparent in the careful and timely presentation of evidenc ...
Cytochrome P4502C9: an enzyme of major importance in human
... value in the prediction of substrate binding. Pharmacophore models of the CYP2C9 active site based on the structures of known substrates and inhibitors (up to 1995) have also been developed using molecular modelling approaches [22–24]. Most, but not all, known drug substrates for CYP2C9 are weak aci ...
... value in the prediction of substrate binding. Pharmacophore models of the CYP2C9 active site based on the structures of known substrates and inhibitors (up to 1995) have also been developed using molecular modelling approaches [22–24]. Most, but not all, known drug substrates for CYP2C9 are weak aci ...
PA Criteria
... patient has unresectable, locally advanced or metastatic disease. For LNETs: tumors are low or intermediate grade (typical or atypical carcinoid) and patient has unresectable or advanced disease (stage IIIb-IV). For breast cancer: 1) patient has hormone receptor positive, HER2-negative metastatic di ...
... patient has unresectable, locally advanced or metastatic disease. For LNETs: tumors are low or intermediate grade (typical or atypical carcinoid) and patient has unresectable or advanced disease (stage IIIb-IV). For breast cancer: 1) patient has hormone receptor positive, HER2-negative metastatic di ...
Cathinone derivatives: A review of their chemistry, pharmacology
... through the 1990s, interest in cathinone-related compounds was restricted to isolated parts of the world, and to a limited number of cathinone-related substances. However, by the middle of the next decade, matters began to change with a number of cathinone derivatives appearing as ‘legal highs’, ini ...
... through the 1990s, interest in cathinone-related compounds was restricted to isolated parts of the world, and to a limited number of cathinone-related substances. However, by the middle of the next decade, matters began to change with a number of cathinone derivatives appearing as ‘legal highs’, ini ...
MEDICATION GUIDE ZEGERID® (ze ger id) (omeprazole / sodium
... as multiple daily doses, and long-term PPI therapy (a year or longer). Patients should use the lowest dose and shortest duration of PPI therapy appropriate to the condition being treated. Patients at risk for osteoporosis-related fractures should be managed according to the established treatment gui ...
... as multiple daily doses, and long-term PPI therapy (a year or longer). Patients should use the lowest dose and shortest duration of PPI therapy appropriate to the condition being treated. Patients at risk for osteoporosis-related fractures should be managed according to the established treatment gui ...
PA Criteria
... patient has unresectable, locally advanced or metastatic disease. For LNETs: tumors are low or intermediate grade (typical or atypical carcinoid) and patient has unresectable or advanced disease (stage IIIb-IV). For breast cancer: 1) patient has hormone receptor positive, HER2-negative metastatic di ...
... patient has unresectable, locally advanced or metastatic disease. For LNETs: tumors are low or intermediate grade (typical or atypical carcinoid) and patient has unresectable or advanced disease (stage IIIb-IV). For breast cancer: 1) patient has hormone receptor positive, HER2-negative metastatic di ...
Hypericum perforatum Monograph
... constituent hyperforin to inhibit synaptosomal reuptake of serotonin, norepinephrine, and dopamine.11,12 Two human pharmacological studies demonstrating an increase in cortisol levels following administration of two different St. John’s wort extracts have recently been reported to support this propo ...
... constituent hyperforin to inhibit synaptosomal reuptake of serotonin, norepinephrine, and dopamine.11,12 Two human pharmacological studies demonstrating an increase in cortisol levels following administration of two different St. John’s wort extracts have recently been reported to support this propo ...